Effective administration route for the deleted form of hepatocyte growth factor To exert its pharmacological effects.
The pharmacokinetics and the pharmacological effects of the deleted form of hepatocyte growth factor (dHGF) after intravenous (iv), subcutaneous (sc), or intramuscular (im) administration (0.25 and 2. 5 mg/kg) were studied in rats. After single iv administration (2.5 mg/kg), dHGF in serum rapidly decreased (alpha- and beta-phase half-life: 3.2 and 26.5 min, respectively). Two to four hours after single sc or im administration (2.5 mg/kg), the serum level of dHGF reached a maximum and then gradually declined (half-life: 2.7 h). The serum levels were not changed by repetitive iv administration, but were dramatically decreased by repetitive sc or im administration. Liver weight and serum levels of total protein, albumin, and HDL-cholesterol were significantly increased by iv administration of dHGF (twice daily for 4 days at 0.25 mg/kg). Sc or im administration of dHGF did not increase these parameters at the same dose, but did significantly at 2.5 mg/kg. These observations suggest that iv administration is the most effective in exerting the pharmacological effects of dHGF among three administration routes. dHGF after iv administration was distributed mainly and rapidly into liver (53.6% of the injected dHGF within 5 min) and was sustained at a higher level in the liver than in plasma. In infusion (0.5 mg/kg/3 h), dHGF level in plasma and liver reached a steady-state 15 and 60 min after starting the infusion, respectively. The steady-state level of dHGF was 7- to 9-fold higher in liver than in plasma, and the higher level in liver was sustained beyond the steady-state.
Uematsu
Y
Y
Research Institute of Life Science, Snow Brand Milk Products Co., Ltd., 519 Shimoishibashi, Ishibashi-machi, Shimotsuga-gun, Tochigi 329-0512, Japan.snowls0@mb.infoweb.ne.jp
Fujise
N
N
Kohsaka
K
K
Masunaga
H
H
Higashio
K
K
D000818:Animals; D002784:Cholesterol / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006207:Half-Life; D017228:Hepatocyte Growth Factor / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology*; D007074:Immunoglobulin G / Q000276:immunology; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008099:Liver / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D008111:Liver Function Tests; D008297:Male; D009929:Organ Size / Q000187:drug effects; D009195:Peroxidase / Q000737:chemistry; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar
D007074:Immunoglobulin G; D017228:Hepatocyte Growth Factor; D002784:Cholesterol; D009195:Peroxidase